title: Achieving KDOQI Guidelines for Hematocrit in HIV-Infected Hemodialysis Patients.
abstract: The primary cause of anemia in HIV-infected patients with ESRD is diminished production of erythropoietin. Although most patients respond to recombinant erythropoietin, the response may be blunted in patients with ESRD and concomitant viral or bacterial infections. Previous studies demonstrated a response to erythropoietin by HIV-infected ESRD patients, but hematocrit levels on average were only 27-29%. We were interested in determining if KDOQI guidelines could be met in these patients. Hematocrits and epogen doses of all HIV-positive patients who were undergoing hemodialysis at the Nassau University Medical Center Dialysis Unit between September 2002 and March 2003 were compared to matched controls in our hemodialysis unit. The hematocrit levels in our population were higher than those reported in earlier papers. In our patient population, the mean hematocrit was 37.5, whereas the mean hematocrit levels in the HIV group in previous papers were 27-29%. HIV-infected patients did require higher erythropoietin dosages than controls, but similar doses were used as compared to previous studies. HIV patients on hemodialysis can achieve KDOQI target hematocrits. The difference in route of iron administration and iron stores may explain the higher hematocrit levels in our HIV patient population as compared to previous trials.
authors.affiliation: Nassau University Medical Center, East Meadow, New York, USA.
authors.forename: Leah
authors.initials: L
authors.lastname: Balsam
authors.forename: Abdel-Moneim
authors.initials: AM
authors.lastname: Attia
authors.forename: Nandini P
authors.initials: NP
authors.lastname: Sharma
mesh_terms: D001741:Black or African American; D000747:Anemia, Hypochromic / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009518:New York; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin